Summary
In a double-blind, randomised, cross-over trial clofibrate and a combination of polyenyl phosphatidyl choline (PPC) plus clofibrate were tested in 67 patients with hyperlipoproteinemia. Each treatment lasted for 4 weeks and was separated by a 4 week placebo period. The daily doses were clofibrate 1.2 g and PPC 1.8 g + clofibrate 1.2 g, respectively. The results revealed that polypenyl phosphatidyl choline prevented the elevation of LDL-cholesterol induced by clofibrate treatment, and that the lipid-lowering potency of the combination did not differ significantly from that of clofibrate. Since elevation of LDL-cholesterol is considered to increase the risk of coronary heart disease, the combination appears to offer a therapeutic advantage. Despite the significance of this clinical observation, a final decision may only be obtained from a prospective, long term investigation in patients with coronary heart disease and hyperlipoproteinemia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zelis, R., Amsterdam, A., Spann, J. F., Mason, D. I.: Type IV hyperlipoproteinemia-Clofibrate without dietary therapy. J. Am. Med. Ass.222, 326–328 (1972)
Strisower, E. H., Adamson, G., Strisower, B.: Treatment of hyperlipidemias. Am. J. Med.45, 488–501 (1968)
Wilson, D. E., Lees, R. S.: Metabolic relationship among the plasma lipoproteins J. clin. Invest.51, 1051–1057 (1972)
Rose, H. G., Haft, G. K., Juliano, J.: Clofibrate-induced low density lipoprotein elevation: Therapeutic implications and treatment by colestipol resin. Atherosclerosis23, 413–427 (1976)
Goldstein, J. L., Schrott, H. G., Harrard, W. R., Bierman, E. L., Motulsky, A. G.: Hyperlipidemia in coronary heart disease. J. clin. Invest.52, 1533–1577 (1973)
Kannel, W. B., Castelli, W. P., Gordon, T., McNamara, P. M.: Serum cholesterol, lipoproteins, and the risk of coronary heart disease. Ann. int. Med.74, 1–12 (1971)
Peeters, H.: The biological significance of the plasma phospholipids. In: Phosphatidylcholine. H. Peeters (ed.), pp. 10–33 Berlin-Heidelberg-New York: Springer 1976
Stegie, R.: Der Paardifferenzen-W-Test zur Wirkungsbeurteilung klinischer Behandlungen in paarigen Stichproben Drug. Res.26, 1708 (1976)
The Coronary Drug Project Research Group. The Coronary Drug Project. Design, methods and baseline results. Circulation47, Suppl. 3 (1973)
The Coronary Drug Project Research Group, Clofibrate and niacin in Coronary heart disease. J. Am. Med. Ass.231, 360–381 (1975)
Ditschuneit, H., Klör, H. U., Ditschuneit, H. H.: Effects of Essential Phospholipids on the Carbohydrate-Induced Hypertriglyceridemia. In: Phosphatidylcholine. H. Peeters (ed.) pp. 98–114. Berlin-Heidelberg-New York: Springer 1976
Blaton, V., Declercq, B., Peeters, H., Vandamme, D., Soetewey, F.: The Human Plasma Lipids and Lipoproteins Under Influence of EPL-Therapy. In: Phosphatidylcholine. H. Peeters, (ed.) pp. 125–132. Berlin, Heidelberg, New York: Springer 1976
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schneider, J., Müller, R., Buberl, W. et al. Effect of polyenyl phosphatidyl choline on clofibrate-induced increase in LDL cholesterol. Eur J Clin Pharmacol 15, 15–19 (1979). https://doi.org/10.1007/BF00563553
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00563553